Urol. praxi. 2023;24(1):17-20 | DOI: 10.36290/uro.2023.013

Management of the metastatic renal cancer

doc. MUDr. Jaroslav Pacovský, Ph.D.
Urologická klinika FN a LF Univerzity Karlovy, Hradec Králové

Metastatic renal cancer is serious disease with serious prognosis. The management covers surgery od primary tumor, eventually on metastasis. Lymphadenectomy has no therapeutical impact; it is useful for staging only. Monoclonal antibody, tyrosinkinase inhibitors, mammalian targets of rapamycin (mTOR) and cytokines can be used for oncological management. The complex therapy needs multidisciplinary cooperation and well-informed patient.

Keywords: renal cancer, metastasis, therapy.

Accepted: March 16, 2023; Published: March 21, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pacovský J. Management of the metastatic renal cancer. Urol. praxi. 2023;24(1):17-20. doi: 10.36290/uro.2023.013.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. www.svod.cz.
    2. Howlader N, Noone AM, Krapcho M (eds). SEER Cancer Statistics Review (CSR) 1975-2018. [online]. Bethesda, MD [vid. 6. 1. 2022]. https://seer.cancer.gov/csr/1975_2018/.
    3. Ghoneim IA, Fergany AF. Minimally invasive surgery for renal cell carcinoma. Expert Rev Anticancer Ther. 2009;9(7):989-997. Go to original source... Go to PubMed...
    4. Chalairat S-O, Hajime T, Yanbo W, et al. Renal cancer surgery in patients without preexistin chronic kidney disease - Is there a survival benefit for partial nephrectomy? J. Urol. 2019;201(6):1088-1096. Go to original source... Go to PubMed...
    5. Študent V, Študentová H. Cytoredukční nefrektomie: možnosti identifikace ideálního kandidáta na základě předoperačních prediktivních faktorů. Ces Urol. 2022;26(1):13-28. Go to original source...
    6. Lahn M, Fisch P, Kouml; hler G, et al. Pro‑Inflammatory and T Cell Inhibitory Cytokines Are Secreted at High Levels in Tumor Cell Cultures of Human Renal Cell Carcinoma. Eur Urol. 1999;35(1):70-80. doi:10.1159/000019821. Go to original source... Go to PubMed...
    7. Bellardita L, Rancati T, Alvisi MF, et al. Predictors of health‑related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol. 2013;64(1):30-36. doi:10.1016/j.eururo.2013. 01. 009. Go to original source... Go to PubMed...
    8. Chapin BF, Delacroix SE, Culp SH, et al. Safety of Presurgical Targeted Therapy in the Setting of Metastatic Renal Cell Carcinoma. Eur Urol. 2011;60(5):964-971. doi:10.1016/j.eururo.2011. 05. 032. Go to original source... Go to PubMed...
    9. Mazzone E, Nazzani S, Preisser F, et al. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. Cancer Epidemiol. 2018;56:118-125. doi:10.1016/j. canep.2018. 08. 006. Go to original source... Go to PubMed...
    10. Lenis AT, Salmasi AH, Donin NM, et al. Trends in usage of cytoreductive partial nephrectomy and effect on overall survival in patients with metastatic renal cell carcinoma. Urol Oncol Semin Orig Investig. 2018;36(2):78.e21-78.e28. doi:10.1016/j.urolonc.2017. 09. 030. Go to original source...
    11. Kroeger N, Pantuck AJ, Wells JC, et al. Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. Eur Urol. 2015;68(3):506-515. doi:10.1016/j.eururo.2014.  054. Go to original source... Go to PubMed...
    12. Gershman B, Thompson RH, Moreira DM, et al. Lymph Node Dissection is Not Associated with Improved Survival among Patients Undergoing Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Propensity Score Based Analysis. J Urol. 2017;197(3 Part 1):574-579. doi:10.1016/j.juro.2016. 09. 074. Go to original source... Go to PubMed...
    13. Whitson J, Harris CR, Reese AC, et al. Lymphadenectomy improves survival of patients with renal cell carcinoma and nodal metastases. J Urol. 2011;185:1615. Go to original source... Go to PubMed...
    14. Bhindi B, Wallis CJD, Boorjian SA, et al. The role of lymph node dissection in the management of renal cell carcinoma: a systematic review and meta‑analysis. BJU Int. 2018;121(5): 684-698. doi:10.1111/bju.14127. Go to original source... Go to PubMed...
    15. Lughezzani G, Capitanio U, Jeldres C, et al. Prognostic significance of lymph node invasion in patients with metastatic renal cell carcinoma. Cancer. 2009;115(24):5680-5687. doi:10.1002/cncr.24682. Go to original source... Go to PubMed...
    16. Freed SZ, Halperin JP, Gordon M. Idiopathic regression of metastases from renal cell carcinoma. J. Urol. 1997;118(4):583-542. Go to original source...
    17. Marcus SG, Choyke PL, Reiter R, et al. Regression of metastatic renal cell carcinoma aftercytereductive nephrectomy. J. Urol. 1993;150:463-466. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.